


**Mometamax Ultra™**

**One Dose. Healthy Ears.  
Happy Dog.**





# About Canine Otitis Externa<sup>1,2</sup>

- Most frequently identified disorder in primary practice<sup>3</sup>
- Inflammation alters the ear canal environment
- Resident bacteria and fungi multiply
- Can affect one ear or both ears to a similar or varying extent

## Common Signs


- Rubbing or scratching ears
- Head shaking
- Pain or discomfort
- Unpleasant odour or discharge

# Otitis Externa Prevalence by the Numbers


- Otitis externa may affect up to **1 in 7** or more dogs seen in general practice<sup>3,4</sup>



- **1 in 4** dogs may experience at least 1 recurrence<sup>4</sup>
- More than **two-thirds** of cases may involve *Staphylococcus pseudintermedius* and/or *Malassezia pachydermatis* with the majority of cases presenting as mixed infections<sup>5,6</sup>



*Staphylococcus pseudintermedius*



*Malassezia pachydermatis*

- Of mixed infection cases, more than **80%** may include *Malassezia pachydermatis*<sup>7</sup>

# Introducing a Trio of Active Ingredients for Treating Canine Otitis Externa



Packaging is for demonstration purposes only and does not reflect the actual packaging registered in every market.





# 3 IN 1

## Convenient Single-Dose Treatment


**Mometamax Ultra™ is a combination of 3 potent active ingredients**

- Gentamicin is a broad-spectrum bactericidal antibiotic
- Posaconazole is the most potent broad-spectrum antifungal
- Mometasone furoate is a high potency topical corticosteroid with few systemic side effects

# Reliable Improvement in Clinical Signs

- Peak concentrations of active ingredients are reached soon after application followed by rapid improvement
- In the clinical field study, of 33 dogs with otitis externa associated with a mixed culture of *Staphylococcus intermedius* and *Malassezia pachydermatis*<sup>8</sup>:
  - **100% HAD HEALTHIER EARS** by 2 weeks after treatment:  
OTIS-3 ear scores of 4/12 or less
  - **100% HAD HEALTHY EARS** by 4 weeks after treatment:  
OTIS-3 ear scores of 3/12 or less\*

## Reduction of veterinary clinical ear scores in a masked randomised multicenter field trial in client-owned dogs with otitis externa



\*Maximum clinical response was seen at 4-6 weeks

# Gentamicin

## Broad-spectrum bactericidal antibiotic

- Rapidly kills susceptible Gram-positive and Gram-negative bacteria, including *Staphylococcus pseudintermedius* and *Pseudomonas aeruginosa*<sup>9</sup>
- Limited evidence for increasing resistance in the field despite widespread topical use in otitis externa<sup>10</sup>





# Posaconazole

## Highest potency antifungal for canine otitis externa

- Rapidly kills susceptible fungi, including *Malassezia pachydermatis*<sup>9</sup>
- The most potent antifungal in current use for canine otitis externa<sup>8,11</sup>

**40-100x  
MORE POTENT**


against *M. pachydermatis* *in vitro* than clotrimazole,  
miconazole, nystatin and terbinafine<sup>8,11,12,13</sup>



# Mometasone Furoate

## High potency topical corticosteroid with few systemic side effects

- A leading corticosteroid for otitis externa with more than 10 years history of veterinary use
- Reduces inflammation and resolves clinical signs (eg, redness, swelling, ulceration and discharge)




# Key Benefits of Mometamax Ultra




## SINGLE DOSE

A single dose of Mometamax Ultra was effective and well-tolerated in client-owned dogs with acute otitis externa or acute flare-ups of recurrent otitis externa.



## FEW LOCAL EFFECTS<sup>13</sup>

Reversible, minimal to mild atrophy of the epidermis of the external ear canal with epithelial lining of the tympanum in dogs administered the recommended treatment dose three times at 2-week intervals.



## WELL TOLERATED<sup>13</sup>

No treatment-related adverse reactions were observed in clinical trials.



## FEW SYSTEMIC EFFECTS<sup>13</sup>

Baseline and ACTH-stimulated cortisol concentrations in dogs administered the recommended treatment dose three times at 2-week intervals were not significantly different from placebo-treated dogs.

Cortisol increased in all groups (3x and 5x) in response to ACTH stimulation after cessation of treatment indicating sufficient adrenal function as well as reversible effects even at higher doses.

# Mometamax Ultra: the Unique, Single-Dose Treatment You Can Count On

## More confidence

- Single-dose treatment
- Unique combination of 3 active ingredients
- Effective and convenient

## Better compliance

- For veterinary professional use only
- 1 in-clinic administration
- No administration struggles at home
- Correct dosage ensured



Mometamax Ultra™

# The Single-Dose, In-Clinic Treatment You Can Count On

- Single-dose, in-clinic treatment ensures full-dose administration
- Unique combination of three proven active ingredients
- Effective and convenient

Talk to your MSD Animal Health representative about how a single-dose, in-clinic administration of Mometamax Ultra can benefit your patients, your clients, and your practice.

## One Dose. Healthy Ears. Happy Dog.

**References:** 1. Kasai T, Fukui Y, Aoki K, et al. *J Appl Microbiol*. 2020;130:1084-1091. 2. Borriello G, Paradiso R, Catozzi C, et al. *PLoS One*. 2020;15:e0241447. 3. O'Neill DG, Church DB, McGreevy PD, et al. *PLoS One*. 2014;9:e90501. 4. Perry LR, MacLennan B, Korven R, et al. *Can Vet J*. 2017;58:168-174. 5. Lyskova P, Vydrzalova M, Mazurova J. *J Vet Med A*. 2007;54:559-563. 6. Szewczuk MA, Zych S, Sablik P. *Slov Vet Res*. 2020;57:33-43. 7. Petrov V, Zhelev G, Marutsov P, et al. *Bulg J Vet Med*. 2018;22:1-10. 8. European Medicines Agency. Mometamax Ultra. EPAR - Product Information & Assessment Report. 2022. 9. Paterson S. *Small Anim Pract*. 2016;57:668-678. 10. Bourelly C, Cozeau G, Jarrige N, et al. *Epidemiol Inf*. 2019;147:1-10. 11. Peano A, Johnson E, Chiavassa E, et al. *J Fungi*. 2020;6:93. 12. Bourdeau P, Marchand AM, Etoire F. *Vet Dermatol*. 2004;15:46. 13. SUMMARY OF PRODUCT CHARACTERISTICS. Mometamax Ultra ear drops suspension for dogs: Summary of product characteristics.

Mometamax Ultra™ contains gentamicin (as sulfate), posaconazole and mometasone furoate (as monohydrate). **POM-V**

Further information is available from the SPC, datasheet or package leaflet.

MSD Animal Health UK Limited. Registered office Walton Manor, Walton, Milton Keynes MK7 7AJ, UK. Registered in England & Wales no. 946942.

Advice should be sought from the medicine prescriber.

**Use medicines responsibly.**

Copyright © 2023 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.

UK-MTMU-23100001



**MSD**  
Animal Health